Literature DB >> 27470657

High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.

Chan Yoon Cheah1,2, David Joske1,2, Gavin Cull1,2, Michael Gilbertson3,4, Stephen S Opat3,4, Constantine S Tam5,6, Andrew Wirth6,7, John F Seymour5,6.   

Abstract

Entities:  

Keywords:  autologous stem cell transplant; central nervous system; diffuse large B-cell lymphoma

Mesh：

Year:  2016        PMID： 27470657     DOI： 10.1111/bjh.14187

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

Authors:  Tarec Christoffer El-Galaly; Chan Yoon Cheah; Mette Dahl Bendtsen; Grzegorz S Nowakowski; Roopesh Kansara; Kerry J Savage; Joseph M Connors; Laurie H Sehn; Neta Goldschmidt; Adir Shaulov; Umar Farooq; Brian K Link; Andrés J M Ferreri; Teresa Calimeri; Caterina Cecchetti; Eldad J Dann; Carrie A Thompson; Tsofia Inbar; Matthew J Maurer; Inger Lise Gade; Maja Bech Juul; Jakob W Hansen; Staffan Holmberg; Thomas S Larsen; Sabrina Cordua; N George Mikhaeel; Martin Hutchings; John F Seymour; Michael Roost Clausen; Daniel Smith; Stephen Opat; Michael Gilbertson; Gita Thanarajasingam; Diego Villa
Journal:  Eur J Cancer       Date:  2018-02-21       Impact factor: 9.162

2.  Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study.

Authors:  Megan Fleming; Ying Huang; Emily Dotson; David A Bond; John Reneau; Narendranath Epperla; Lapo Alinari; Jonathan Brammer; Beth Christian; Robert A Baiocchi; Kami Maddocks; Yazeed Sawalha
Journal:  Ther Adv Hematol       Date:  2022-07-23

3.  Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.

Authors:  XiaoQin Wu; XinYue Zhang; RenDe Xun; MengSi Liu; Zhen Sun; JianChao Huang
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.